Abstracts tagged "PRO"

Abstract Number: 1531 • 2017 ACR/ARHP Annual Meeting
Effects of Intravenous Golimumab on Patient-Reported Outcomes in Active Ankylosing Spondylitis: 28-Week Results of the Phase 3 Trial
John D. Reveille¹, Atul A. Deodhar², Eric K.H. Chan³, Steven Peterson⁴, Nan Li⁴, Elizabeth C. Hsia⁵, Lilianne Kim⁴, Kim Hung Lo⁴, Diane D. Harrison⁴ and Chenglong Han⁶, ¹University of Texas McGovern Medical School, Houston, TX, ²Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, ³Janssen Global Services, LLC, Raritan, NJ, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁶Janssen Global Services, LLC, Malvern, PA
Background/Purpose: To evaluate patient-reported outcomes (PRO) of physical functioning, mental health functioning, health state, and health-related quality of life (HRQoL) in patients (pts) with active…
Abstract Number: 2248 • 2017 ACR/ARHP Annual Meeting
Function, Pain, Fatigue, and Participation Are the Primary Contributors to the Patient Global Assessment in Rheumatoid Arthritis
Ethan Craig¹, Susan J. Bartlett², Jamie Perin³, Scott Zeger³ and Clifton O. Bingham III¹, ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ³Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD
Background/Purpose: The patient global assessment (PGA) is widely used in disease activity scores for RA, including the CDAI, SDAI, and DAS28. While pain has been…
Abstract Number: 2463 • 2017 ACR/ARHP Annual Meeting
Golimumab in Biologic-NaïVe Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Subanalysis from a Non-Interventional Evaluation in Germany
Klaus Krüger¹, Gerd R. Burmester², Siegfried Wassenberg³, Martin Bohl-Buehler⁴ and Matthias H. Thomas⁵, ¹Praxiszentrum St. Bonifatius München, München, Germany, ²Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ³Rheumazentrum Ratingen, Ratingen, Germany, ⁴Friedrich-Ebert-Str. 35, Rheumahaus, Potsdam, Germany, ⁵Medical Affairs, MSD Sharp & Dohme GmbH, Bünde, Germany
Background/Purpose: Golimumab (GLM) has demonstrated efficacy and safety in several randomized clinical trials with biologic-naïve patients (pts.). However, more data regarding the effectiveness and patient-reported…
Abstract Number: 2539 • 2017 ACR/ARHP Annual Meeting
The Contribution of Skin and Joint Improvements to the Health-Related Quality of Life of Patients with Active Psoriatic Arthritis
Arthur Kavanaugh¹, Alice B Gottlieb², Akimichi Morita³, Joseph Merola⁴, Julie Birt⁵, Chen-Yen Lin⁵, Catherine Shuler⁵ and Diamant Thaçi⁶, ¹Medicine, University of California, San Diego, La Jolla, CA, ²Department of Dermatology, New York Medical College, Vallhalla, NY, ³Dept of Geriatric & Environmental Dermatology, Nagoya City Univ Medical School, Nagoya, Japan, ⁴Clinical Unit for Research Innovation & Trials, Harvard Medical School, Boston, MA, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein Campus Luebeck, Ratzeburger Allee, Germany
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease affecting peripheral and axial joints. For patients with active psoriasis, the added burden of skin…
Abstract Number: 2548 • 2017 ACR/ARHP Annual Meeting
Validation of New Potential Targets for Remission and Low Disease Activity in Psoriatic Arthritis in Patients Treated with Golimumab
Laura C Coates¹, Proton Rahman², Eliofotisti Psaradellis³, Emmanouil Rampakakis³, Brendan Osborne⁴, Allen J Lehman⁵ and Francois Nantel⁴, ¹LIRMM, University of Leeds, Leeds, United Kingdom, ²Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, ³JSS Medical Research, Montreal, QC, Canada, ⁴Medical Affairs, Janssen Inc., Toronto, ON, Canada, ⁵Janssen Inc., Toronto, ON, Canada
Background/Purpose: Treat to target recommendations in PsA state that the target of treatment should be remission or low disease activity (LDA). So far, the only…
Abstract Number: 2549 • 2017 ACR/ARHP Annual Meeting
Achievement of Minimal Disease Activity Is Associated with Improvements in Health-Related Quality of Life and Productivity in Psoriatic Arthritis Patients
Laura C Coates¹, Ana-Maria Orbai², Julie Birt³, Lisa Kerr³, Olivier Benichou³ and Philip S. Helliwell⁴, ¹University of Oxford, Leeds, Great Britain, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Eli Lilly and Company, Indianapolis, IN, ⁴School of Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Treatment goals in psoriatic arthritis (PsA) are moving toward attainment of absolute therapeutic thresholds rather than relative improvement. Minimal disease activity (MDA), a composite…
Abstract Number: 335 • 2017 ACR/ARHP Annual Meeting
Psoriatic Arthritis Patients Who Attain a Very Low Disease Activity State Have a Minimal Impact of the Disease on Their Lives
Rubén Queiro¹, Juan D. Cañete², Carlos Alberto Montilla-Morales³, Miguel A. Abad⁴, Susana Gomez Castro⁵ and Ana Cabez⁵, ¹Rheumatology Department. Hospital Universitario Central de Asturias, Oviedo, Spain, ²Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain, ³Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ⁴Rheumatology, HU. Virgen del Puerto., Plasencia, Spain, ⁵Pfizer, Madrid, Spain
Background/Purpose: The target of treatment in psoriatic arthritis (PsA) should be remission or inactive disease. A potential definition that would fit with the Treat-to-Target Recommendations…
Abstract Number: 597 • 2017 ACR/ARHP Annual Meeting
Ixekizumab Improves Patient-Reported Outcomes through 52 Weeks in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to Tumor Necrosis Factor-Inhibitors
Arthur Kavanaugh¹, Helena Marzo-Ortega², Ronald Vender³, Julie Birt⁴, David Adams⁴, Olivier Benichou⁴, Chen-Yen Lin⁴ and Peter Nash⁵, ¹Medicine, University of California, San Diego, La Jolla, CA, ²Department of Rheumatology, Chapel Allerton Hospital, Leeds, United Kingdom, ³Dermatrials Research, Inc., Hamilton, ON, Canada, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵University of Queensland, Brisbane, Australia
Background/Purpose: Ixekizumab (IXE) is a high affinity monoclonal antibody that selectively targets interleukin-17A. Up to 24 weeks, IXE was superior to placebo (PBO) in improving…
Abstract Number: 612 • 2017 ACR/ARHP Annual Meeting
Safety and Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis over a 6 Month Period
Regan Arendse¹, Anna Jaroszynska², Derek Haaland³, Pauline Boulos⁴, Isabelle Fortin⁵, Raheem Kherani⁶, Ariel Masetto⁷, Jonathan Chan⁸, Eliofotisti Psaradellis⁹, Melissa Stutz⁹, Brendan Osborne¹⁰, Francois Nantel¹⁰ and Allen J Lehman¹¹, ¹University of Saskatchewan, Saskatoon, SK, Canada, ²Private practice, Burlington, ON, Canada, ³Rheumatology, Clinical Immunology & Allergy, McMaster University, Barrie, ON, Canada, ⁴Rheumatology, McMaster University, Hamilton, ON, Canada, ⁵Centre de Rhumatologie De l’Est du Quebec, Rimouski, QC, Canada, ⁶University of British Columbia, Richmond, BC, Canada, ⁷Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ⁸Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹¹Janssen Inc., Toronto, ON, Canada
Background/Purpose: Ustekinumab (UST) is a fully human immunoglobin monoclonal antibody against interleukin-12 (IL-12) and interleukin-23 (IL-23) that has been proven safe and efficacious for the…
Abstract Number: 103 • 2016 ACR/ARHP Annual Meeting
People with Rheumatoid Arthritis Recruited from an Online Patient Community May Differ from Clinical Populations in Symptoms and Impacts
Anna Kristina Gutierrez¹, Susan J. Bartlett^1,2, Michelle Jones³, W. Benjamin Nowell⁴, Seth D. Ginsberg⁴, Vivian P. Bykerk⁵, Jeffrey R. Curtis⁶ and Clifton Bingham III⁷, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Global Healthy Living Foundation, CreakyJoints, Upper Nyack, NY, ⁵Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Johns Hopkins University, Baltimore, MD
Background/Purpose: Patients are increasingly recruited from online communities to provide insight regarding their lived experiences and preferences for treatment and services. We compared physical, social,…
Abstract Number: 539 • 2016 ACR/ARHP Annual Meeting
Promis Short Forms Are Relevant to People Living with RA: Results of Cognitive Debriefing Interviews
Anna Kristina Gutierrez¹, Susan J. Bartlett^1,2, Alessandra Butanis³, Vivian P. Bykerk⁴, Jeffrey R. Curtis⁵, Amye L. Leong⁶, Anne Lyddiatt⁷ and Clifton Bingham III⁸, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Strategic Relations, Bone & Joint Decade, Santa Barbara, CA, ⁷Musculoskeletal Group, Cochrane Collaboration, Hamilton, ON, Canada, ⁸Johns Hopkins University, Baltimore, MD
Background/Purpose: PROMIS® measures were developed to assess physical, mental, and social health across chronic diseases and include brief short forms (SFs; 4-8 items) to assess…
Abstract Number: 591 • 2016 ACR/ARHP Annual Meeting
Patient-Reported Outcomes for Etanercept Therapy in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment
Louis Bessette¹, Majed Khraishi², Alan J Kivitz³, Arunan Kaliyaperumal⁴, Rama Grantab⁵, Melanie Poulin-Costello⁵, Maya Isaila⁵ and David Collier⁴, ¹Rhumatology, Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ²Medical Consultants of West Newfoundland, Western Memorial Hospital, Corner Brook, NF, Canada, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Amgen Canada Inc., Mississauga, ON, Canada
Background/Purpose: When a tumor necrosis factor inhibitor (TNFi) fails in a patient with moderate to severe rheumatoid arthritis (RA), new American College of Rheumatology (ACR)…
Abstract Number: 1417 • 2016 ACR/ARHP Annual Meeting
Back to Feeling Normal Again: Patients with Rheumatoid Arthritis in Remission
Linda Rasch¹, Maarten Boers^2,3, Willem F. Lems^1,2, Samina Turk⁴, Dirkjan van Schaardenburg^2,5, Tessa Sanderson⁶, Sarah Hewlett⁶ and Lilian van Tuyl¹, ¹Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, Amsterdam, Netherlands, ³Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ⁴Rheumatology, Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, Amsterdam, Netherlands, ⁵Clinical Immunology & Rheumatology F4.105, Amsterdam Rheumatology and immunology Center | Academic Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ⁶Nursing and Midwifery, University of the West of England, Bristol, United Kingdom, Bristol, United Kingdom
Background/Purpose: The American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) definition of remission in rheumatoid arthritis (RA) [1] lacks information on patient perceived remission [2].…
Abstract Number: 1741 • 2016 ACR/ARHP Annual Meeting
Patients with Active Psoriatic Arthritis Achieving Minimal Disease Activity with Secukinumab Treatment Demonstrate Sustained Improvement of Function and Quality of Life
Laura C. Coates¹, Philip J Mease², Laure Gossec³, Bruce Kirkham⁴, Lawrence Rasouliyan⁵, Shephard Mpofu⁶, Steffen Jugl⁶, Chetan Karyekar⁷ and Kunal Gandhi⁷, ¹University of Leeds, Leeds, United Kingdom, ²Rheumatology and Internal Medicine, Swedish Medical Center and University of Washington, Seattle, WA, ³Rheumatology Department, Hôpital Pitié Salpêtrière, Paris 06 University, Paris, France, ⁴Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ⁵RTI Health Solutions, Barcelona, Spain, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Secukinumab, a fully human anti–IL-17A monoclonal antibody, previously demonstrated higher minimal disease activity (MDA)1 response rates and sustained improvements in patient reported outcomes2 among…
Abstract Number: 2373 • 2016 ACR/ARHP Annual Meeting
Patient Preference for Display of Electronic Patient-Reported Outcomes in Osteoarthritis Clinical Trials: Wording Emphasis, Question Format, and Navigation Button Placement
Laura Khurana¹, Ellen Durand¹, Sarah Gary¹, Tony Otero¹, Chris Hall¹, Aisling Ryan², Christopher J. Evans² and Susan Dallabrida¹, ¹ERT, Boston, MA, ²Endpoint Outcomes, Boston, MA
Background/Purpose: Electronic patient-reported outcomes (ePROs) are a reliable method for collecting patient data in osteoarthritis clinical trials and offer many advantages over paper collection; however,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].